News – Desmond Tutu HIV Foundation

May202020

DTHC CELEBRATES NEWS THAT LONG-ACTING INJECTABLE PrEP IS EFFECTIVE FOR THE PREVENTION OF HIV INFECTION IN CISGENDER MEN AND TRANSGENDER WOMEN

May 20, 2020

18 MAY 2020 – The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and…

Details

The DTHF Remembers World-renowned HIV scientist, Professor Gita Ramjee

April 1, 2020

The Desmond Tutu HIV Foundation is deeply saddened by the news of Professor Gita Ramjee’s untimely passing due to complications arising from COVID-19. Professor Ramjee was Chief Scientific Officer at the Aurum Institute and former chief specialist scientist and director of the South African Medical Research Council’s HIV Prevention Unit. She was a fundamental figure…

Details

Apr12020

Feb142020

What the discovery of a new HIV strain means for the pandemic

February 14, 2020

Linda-Gail Bekker, University of Cape Town The discovery of a rare new strain of HIV for the first time in nearly 20 years recently made headlines around the world. The big question is what the discovery means for the overall response to the HIV epidemic. A team of US researchers from Abbott, an American medical…

Details

HVTN702 HIV Vaccine Trial Discontinued

February 4, 2020

The Desmond Tutu HIV Centre greets with great disappointment the news that the Phase 2b/3 HIV vaccine study HVTN 702 conducted by the HIV Vaccine Trials Network has been stopped by the National Institute of Allergy and Infectious Diseases (NIAID), the trial sponsors. The decision comes after a recommendation from the independent Data and Safety…

Details

Feb42020